Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.41 |
| ▸ | CDC42 | P60953 | 1/20 | 0.41 |
| ▸ | RAC1 | P63000 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376492 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP11B1CYP11B2TSHROPRK1 | |
| SCHEMBL8681937 | 0.82 | DRD3 (0.60) | KMT2A | |
| SCHEMBL11529154 | 0.80 | PTGS2 (0.47) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| SCHEMBL27559442 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| SCHEMBL29111695 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| Isoprofen SCHEMBL287354 | 0.78 | PTGS2 (0.46) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| SCHEMBL12376490 | 0.78 | KARS1 (0.42) | CYP1A2CYP11B1CYP11B2TSHRKMT2A | |
| Isoprofen SCHEMBL11727169 | 0.77 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| Isoprofen SCHEMBL11377622 | 0.77 | PTGS2 (0.45) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 | |
| SCHEMBL1346172 | 0.76 | PTGS2 (0.44) | PTGS2PTGS1CYP1A2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172558-A1 | NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172558-A1 | NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172558-A1 | NAPROXEN-BASED CHIRAL COMPOUNDS AND LIQUID CRYSTAL DISPLAY APPLICATIONS | CRY1, CRY2, ALOX5 | PTGS2 553/4885PTGS1 624/4885CYP1A2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.